Orexigen (OREX) Pops Higher on Analyst Upgrade; Volatility Up
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics (Nasdaq: OREX) is ripping higher out of the gate Thursday, following positive late-day news tied to Arena Pharma's (Nasdaq: ARNA) lorcaserin weight-loss drug Wednesday. JPMorgan upgraded the stock to Overweight earlier.
Volatility is up 77.5 percent with shares about 12 percent positive on the session early.
Volatility is up 77.5 percent with shares about 12 percent positive on the session early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: Iran conflict is working out very well, talks going on at request of Iran
- Pfizer (PFE) call put ratio 1.1 calls to 1 put into quarter results
- SpaceX (SPCX) call put ratio 1.2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, Options, Trader TalkRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
